Clinical Trials on Microbial Keratitis in South Africa

Total 505 results

Amgen

Active, not recruiting

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis

United States
AbbVie

Active, not recruiting

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis (Flex-Up)

Atopic Dermatitis

Australia, Belgium, Bulgaria, Canada, China, Germany, Hungary, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Slovakia, Spain, Taiwan, United Kingdom, Japan
AbbVie

Completed

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (Heads Up)

Atopic Dermatitis

United States, Australia, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Spain, Sweden, Taiwan, Ukraine, United Kingdom
JW Pharmaceutical
LEO Pharma

Completed

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland, Spain, Australia, Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) (Liberty AD)

Dermatitis, Atopic

United States, Germany, Poland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

Dermatitis Atopic

Spain, Czechia, Italy, Israel, Argentina, Australia, Austria, Belgium, Colombia, Finland, France, Greece, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Debiopharm International SA

Completed

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Chronic Pain | Hepatitis C

United States, Belgium, Germany, Taiwan, Australia, France, Thailand, Puerto Rico, United Kingdom, Italy, India, Poland, Korea, Republic of, Canada
Debiopharm International SA

Completed

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Hepatitis C

United States, Romania, Belgium, Germany, Hungary, Taiwan, Spain, Italy, Australia, France, Hong Kong, Thailand, Korea, Republic of, United Kingdom, Argentina, Russian Federation, Canada, Poland, Puerto Rico, Vietnam, Mexico
Amgen

Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Atopic Dermatitis

United States, Japan, Korea, Republic of, Australia, Taiwan, Spain, Switzerland, Germany, Croatia, Austria, Bulgaria, Italy, France, Belgium, Denmark, China, Netherlands, Singapore, Hungary, Czechia, Poland, Brazil, Greece, Portugal, Fi... and more
GlaxoSmithKline

Completed

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

Dermatitis, Atopic

United States, Canada, Japan
Incyte Corporation

Completed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Atopic Dermatitis

United States, Canada
Actavis Inc.

Completed

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Japan
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

Atopic Dermatitis

United States
Dermavant Sciences GmbH

Completed

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Atopic Dermatitis

United States, Canada
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Atopic Dermatitis

United States, Germany, Belgium, Canada, Spain, United Kingdom, Poland, Netherlands
Galderma R&D

Completed

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Belgium, Bulgaria, Estonia, France, Georgia, Germany, Hungary, Italy, Poland, Singapore
Eli Lilly and Company
Dermira, Inc.

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)

Eczema | Atopic Dermatitis

United States, Taiwan, Spain, Australia, Mexico, Canada, Germany, Japan, Brazil, Argentina, Poland, Czechia, France
Pfizer

Active, not recruiting

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Dermatitis, Atopic

China, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
Regeneron Pharmaceuticals
Sanofi

Completed

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

Atopic Dermatitis

Hungary, Netherlands, Spain, United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Lithuania, New Zealand, ... and more
Bellus Health Inc

Completed

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (BLUEPRINT)

Atopic Dermatitis | Chronic Pruritus

United States, Canada
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Sight Sciences, Inc.

Active, not recruiting

Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

Dry Eye | Meibomian Gland Dysfunction

United States
Exact Sciences Corporation

Recruiting

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Hepatitis B | Hepatocellular Carcinoma | Cirrhosis | Liver Cancer | Hepatocellular Cancer

United States
Amgen

Active, not recruiting

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)

Atopic Dermatitis

Belgium, Spain, China, Germany, United States, Austria, France, Hungary, Switzerland, Canada, United Kingdom, Bulgaria, Australia, Netherlands, Malaysia, Singapore, Slovenia, Italy, Japan, Argentina, Greece, Turkey, Poland, Puerto Rico, Romani... and more
Dermavant Sciences GmbH

Completed

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Atopic Dermatitis

United States, Canada
Eli Lilly and Company
Dermira, Inc.

Completed

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Eli Lilly and Company

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)

Eczema | Atopic Dermatitis

United States, Taiwan, Spain, Mexico, Japan, Brazil, Australia, Canada, Czechia, France, Germany, Argentina, Poland
Senju Pharmaceutical Co., Ltd.

Completed

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

Dry Eye Syndromes

United States
Allergan

Terminated

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Dry Eye Syndromes

United States
Galderma R&D

Terminated

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

Keratosis, Actinic

United States, Puerto Rico
Eli Lilly and Company

Terminated

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (ADmIRe)

Atopic Dermatitis

Spain, Puerto Rico, United States, Canada, Japan, Italy, Argentina, Austria, Czechia, France, Germany, Hungary, Mexico
Hoffmann-La Roche

Completed

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Canada, United Kingdom, Germany, Australia, Poland, Finland, France, Spain, Switzerland, Czechia, Netherlands, Taiwan
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-1)

Hepatitis C

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Eli Lilly and Company
Dermira, Inc.

Completed

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

Atopic Dermatitis

United States, Canada, Germany, Poland
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada
Eli Lilly and Company
Dermira, Inc.

Completed

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (ADore)

Atopic Dermatitis

United States, Canada, Australia, Poland
LEO Pharma

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Atopic Dermatitis

United States, Belgium, Canada, Australia, France, Germany, Japan, Netherlands, Poland, United Kingdom
Vyne Therapeutics Inc.

Completed

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis (ATOMIK)

Pruritus | Atopic Dermatitis

United States
Sanofi

Recruiting

Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)

Dermatitis Atopic

Norway, Spain, Argentina, Israel, Greece, United States, Australia, Brazil, Canada, China, Colombia, Denmark, France, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation
AbbVie

Recruiting

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis (AD-VISE)

Atopic Dermatitis

Australia, Austria, Canada, Spain, Switzerland, Taiwan, United Arab Emirates, Poland, Czechia, Greece, Russian Federation, Italy, Israel, Argentina, Hungary, Mexico
LEO Pharma

Recruiting

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, France, Germany, Japan, Poland, United Kingdom, Czechia, Spain, Romania, Hungary
GlaxoSmithKline

Completed

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Hepatitis A

United States
Sylentis, S.A.

Completed

Safety Study of Tivanisiran to Treat Dry Eye (FYDES)

Dry Eye Disease

United States
Shire

Completed

Safety Study of Lifitegrast to Treat Dry Eye (SONATA)

Dry Eye Disease

United States
Erasmus Medical Center
Leiden University Medical Center; Medical Center Haaglanden; Rijnstate Hospital; Maasstadziekenhu... and other collaborators

Recruiting

HIV Indicator Diseases in Hospital and Primary Care (#AwareHIV)

HIV Infections | Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Pneumonia | Psoriasis | Weight Loss | Thrombocytopenia | Leukopenia | Dermatitis, Seborrheic | Herpes Zoster | Lymphadenopathy | Uterine Cervical Dysplasia | Primary Health Care | Diarrhea Chronic | Candida Infection | Infectious... and other conditions

Netherlands
Amgen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

Atopic Dermatitis

Korea, Republic of, United States, Turkey, Hong Kong, United Kingdom, Australia, Brazil, Canada, Argentina
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Hungary, Korea, Republic of, Germany, Japan, Poland, Australia, Canada, Czechia, Spain, United Kingdom

Clinical Trials on Microbial Keratitis in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations